Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases

BACKGROUND: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases. METHODS: In this cross-sectional study, 242 obese/overweight and 85 non-obese individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabir, Ali, Pazouki, Abdolreza, Jafari, Motahareh, Mokhber, Somayye, Vaziri, Mohammad, Alavian, Seyed Moayed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392223/
https://www.ncbi.nlm.nih.gov/pubmed/27805073
http://dx.doi.org/10.18869/acadpub.ibj.21.3.197
Descripción
Sumario:BACKGROUND: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases. METHODS: In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran. RESULTS: Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher percentage of hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012). CONCLUSION: The level of anti-HBs surface antigen antibody’s titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.

Ejemplares similares